FOLH1 and pachyonychia congenita: These findings support the use of PSMA PET/CT for MTD; the concept that oligometastatic disease may have a different biological potential without a fully developed metastatic power has arisen since a 1995 study by Hellmann et al. [24], and at this stage there may still be the possibility to have a curative intent for PC [19].